Where India is going wrong in its goal to find new drugs
Understanding the basic biology of a disease is the key to finding new drugs, but in India, we have a dismal record in this area, due to critical gaps: reliance on biological data from Western populations, and inadequate support for local basic research
360° Perspective Analysis
Deep-dive into Geography, Polity, Economy, History, Environment & Social dimensions — AI-powered, on-demand
Context
India is pivoting its pharmaceutical strategy from being the 'pharmacy of the world' (focused on generic drug manufacturing) to fostering high-value innovation and indigenous drug discovery. This shift is driven by new policy frameworks like the (2023), the , and the (2024), recognizing that fundamental research is crucial for developing novel therapeutics, particularly for rare genetic disorders.
UPSC Perspectives
Economic
India currently holds a significant global position in pharmaceutical manufacturing, accounting for about 20% of the global generic medicine supply by volume. However, the industry suffers from a value gap, contributing only ~3.4% by value. This indicates a heavy reliance on low-margin generic manufacturing rather than high-margin, patent-protected innovation. The , launched with an outlay of ₹5,000 crore for five years (2023-24 to 2027-28), aims to address this by incentivizing research in priority areas like new chemical entities, precision medicine, and orphan drugs (drugs for rare diseases). For UPSC aspirants, understanding this transition is crucial: it represents a shift from a 'volume-based' to a 'value-based' economic model in the pharma sector, requiring substantial investment in Research and Development (R&D) and intellectual property creation to ensure long-term global competitiveness.
Governance
The transition to an innovation-driven pharma ecosystem requires robust and agile regulatory frameworks. The article highlights the modernization of clinical trial rules as a critical step. Historically, India's regulatory environment for clinical trials has faced criticism for being slow and complex, hindering rapid drug development. Recent efforts aim to streamline these processes while ensuring patient safety, aligning with global standards. Furthermore, the newly approved (Biotechnology for Economy, Environment and Employment) signifies a strategic governance approach. This policy focuses on fostering high-performance biomanufacturing to promote a circular bioeconomy, addressing not only healthcare needs but also broader sustainability goals. From a governance perspective, UPSC often tests the ability of regulatory bodies (like the ) to balance the need for rapid medical innovation with stringent ethical and safety oversight.
Social
The emphasis on fundamental research is directly linked to addressing critical public health challenges, particularly the development of treatments for rare genetic disorders (often termed 'orphan diseases'). Because these diseases affect a small percentage of the population, they are historically underfunded by private pharmaceutical companies due to perceived low profitability. By actively promoting research in these areas through government schemes, India is addressing a significant gap in healthcare equity. The shift towards precision medicine—tailoring medical treatment to the individual characteristics of each patient—promises more effective interventions and reduced adverse reactions. This is highly relevant for GS Paper 2 (Health), as it demonstrates a policy shift from a one-size-fits-all generic approach to targeted, high-efficacy healthcare, directly impacting the quality of life and the right to health under of the Constitution.